Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Letue35 

Discuss Cytokinetics Inc.

Cytokinetics Inc.

WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

61,50 €
1,65 %

Einschätzung Buy
Rendite (%) -19,08 %
Kursziel 83,06
Veränderung
Endet am 28.12.24

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Raymond James from $63.00 to $92.00. They now have an "outperform" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -18,54 %
Kursziel 94,52
Veränderung
Endet am 22.01.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Mizuho from $80.00 to $103.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -13,38 %
Kursziel 99,73
Veränderung
Endet am 28.02.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $108.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -10,87 %
Kursziel 86,72
Veränderung
Endet am 28.02.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $94.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -6,82 %
Kursziel 98,59
Veränderung
Endet am 04.03.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $107.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 2,50 %
Kursziel 90,93
Veränderung
Endet am 06.03.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Mizuho from $103.00 to $99.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -9,56 %
Kursziel 79,21
Veränderung
Endet am 08.04.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $86.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -9,56 %
Kursziel 99,24
Veränderung
Endet am 09.04.25

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $108.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat